Skip to main content
Daily Report

Daily Sepsis Research Analysis

02/24/2026
3 papers selected
26 analyzed

Analyzed 26 papers and selected 3 impactful papers.

Summary

Three high-impact sepsis studies stand out today: a PNAS mechanistic study reveals sex-biased disease tolerance via mitochondrial metabolism with doxycycline normalizing male vulnerability; an NPJ Digital Medicine paper introduces a first sepsis-specific multimodal embedding that generalizes across datasets for robust 28-day prediction; and an Advanced Science study identifies a platelet HSP90α–TLR4–autophagy pathway driving NET-mediated thromboinflammation, offering a therapeutic target.

Research Themes

  • Sex differences and disease tolerance in sepsis
  • Multimodal machine learning for sepsis phenotyping and prognosis
  • Platelet–neutrophil crosstalk and immunothrombosis (NETs) as therapeutic targets

Selected Articles

1. Differential disease tolerance mediates sex-biased illness severity in sepsis.

85.5Level VCohort
Proceedings of the National Academy of Sciences of the United States of America · 2026PMID: 41734079

Using murine sepsis models, the authors show that male-biased severity stems from impaired disease tolerance driven by deficient mitochondrial oxidative metabolic shifts, independent of pathogen control and canonical inflammation. Pharmacologic enhancement of mitochondrial tolerance with doxycycline abrogated sex differences by preferentially improving outcomes in males.

Impact: It reframes sex-biased sepsis outcomes around disease tolerance and identifies a mitochondria-focused, druggable axis that normalizes male vulnerability.

Clinical Implications: Sepsis trials and care pathways should incorporate sex-stratified analyses and consider therapeutics that enhance mitochondrial tolerance (e.g., doxycycline), with careful dose–response and safety assessment.

Key Findings

  • Male mice exhibited greater illness severity and organ dysfunction due to impaired disease tolerance, linked to blunted tolerogenic shifts in mitochondrial oxidative metabolism.
  • Sex differences in outcomes were independent of pathogen resistance and canonical immune/inflammatory dysregulation.
  • Doxycycline enhanced mitochondrial tolerance and preferentially reduced illness severity and organ dysfunction in males, eliminating sexual dimorphism.

Methodological Strengths

  • Rigorous in vivo mechanistic dissection separating disease tolerance from resistance pathways across sexes
  • Therapeutic intervention (doxycycline) tested with functional organ outcomes

Limitations

  • Preclinical murine models limit direct human translatability
  • Doxycycline’s pleiotropy and optimal dosing/safety in sepsis remain undefined in humans

Future Directions: Validate mitochondrial tolerance biomarkers and test sex-stratified, dose-finding trials of tolerance-enhancing agents (e.g., tetracyclines) in human sepsis.

Sepsis in humans, as well as mouse models of infection, demonstrates sex-biased outcomes in which males tend to have a higher incidence, higher severity, and higher mortality compared to females. Despite this important sex-bias in sepsis outcomes, little is known about its mechanistic drivers nor therapeutic implications. Much of the foundational data on sepsis pathogenesis is derived from animal studies that included only male subjects, potentially contributing to the notable paucity of successful mouse-to-human translation of sepsis therapeutics. In this study, we demonstrate that male-biased illness severity and organ dysfunction in mouse models of bacterial sepsis are mediated by impaired disease tolerance in males, involving impaired tolerogenic shifts in mitochondrial oxidative metabolism compared to females. Microbiological and immunological analyses of sepsis between males and females revealed that sex-biased disease tolerance was independent of infection resistance mechanisms, as well as canonical immune/inflammatory dysregulation. Therapeutic potentiation of mitochondrial tolerance with doxycycline neutralized sexual dimorphism of illness severity and organ dysfunction through a male-predominant treatment effect. These data reveal that biological sex is a fundamental determinant of illness severity and treatment responsiveness in sepsis through modulation of disease tolerance, which may be

2. A multimodal embedding model for sepsis data representation.

81.5Level IICohort
NPJ digital medicine · 2026PMID: 41731020

SepsisDRM jointly embeds tabular and free-text clinical data, yielding four clinically interpretable phenotypes and robust 28-day risk prediction that generalizes across retrospective, prospective, and external cohorts. As a first sepsis-specific embedding, it enables task-agnostic reuse and lays groundwork for deployable clinical decision support.

Impact: Introduces a generalizable, interpretable multimodal representation that overcomes siloed task-specific models and leverages clinical text—often untapped in sepsis modeling.

Clinical Implications: Supports improved triage and risk stratification by integrating notes with structured data; prospective, workflow-integrated trials are warranted before routine deployment.

Key Findings

  • Developed the first sepsis-specific multimodal embedding that integrates tabular and textual data.
  • Identified four clinically interpretable phenotypes from embedded patient representations.
  • Achieved strong 28-day prediction performance with AUC 0.92 (retrospective), 0.94 (prospective), and 0.78 (external validation) without task-specific tuning.

Methodological Strengths

  • Large training cohort (19,526 patients) with prospective and external validations
  • Joint modeling of structured and unstructured clinical data enabling interpretability and generalization

Limitations

  • Model trained and evaluated on observational datasets; potential dataset shift and documentation bias
  • Clinical impact not yet tested in real-time, randomized, or interventional settings

Future Directions: Prospective, workflow-embedded impact trials; fairness and robustness audits across hospitals; integration with bedside alerts and clinician-in-the-loop calibration.

Sepsis research has long been constrained by limited labeled data and models designed for specific tasks that primarily rely on tabular inputs, overlooking the valuable insights contained in clinical text. To address these limitations, we propose the Sepsis Data Representation Model (SepsisDRM), an embedding model that jointly processes tabular and textual data to capture comprehensive patient representations. Trained on a dataset comprising 19,526 sepsis patients, SepsisDRM demonstrates strong generalization across diverse sepsis-related tasks without task-specific tuning. It effectively stratifies patients into four clinically interpretable phenotypes and achieves robust performance in predicting 28-day outcomes, with AUC scores of 0.92, 0.94, and 0.78 on retrospective, prospective, and external datasets, respectively. As the first embedding model developed specifically for sepsis, SepsisDRM establishes a novel paradigm for sepsis research and offers a promising approach for studies in other fields that involve the integration of both tabular and textual data.

3. Activated Platelet-Released Heat Shock Protein 90α Triggers Autophagy-Dependent Neutrophil Extracellular Trap Formation and Amplifies Sepsis.

80Level VCohort
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026PMID: 41732887

Patient platelet proteomics and mechanistic studies reveal that extracellular HSP90α released from activated platelets binds neutrophil TLR4, activates MyD88–Beclin1 signaling, induces autophagy-dependent NETs, and drives thromboinflammation. Neutralizing HSP90α curtails NETs and sepsis-related thrombosis, nominating a targetable platelet–neutrophil axis.

Impact: Defines a previously unrecognized platelet-derived DAMP pathway linking HSP90α to NETosis and immunothrombosis and demonstrates therapeutic attenuation via antibody blockade.

Clinical Implications: HSP90α could serve as a biomarker and therapeutic target to mitigate NET-driven coagulopathy and organ injury in sepsis; translational safety and efficacy studies are required.

Key Findings

  • Platelet proteomics in sepsis revealed increased HSP90α, originating from megakaryocyte trafficking and translocated to platelet membranes upon activation.
  • Extracellular HSP90α binds neutrophil TLR4, activates MyD88–Beclin1 signaling, induces autophagy, and triggers NET formation.
  • Neutralizing extracellular HSP90α significantly reduced NETs and sepsis-related thrombosis/inflammation in vitro and in vivo.

Methodological Strengths

  • Multi-omic and multi-system validation from patient-derived platelets to in vitro and in vivo functional assays
  • Mechanistic delineation from receptor engagement (TLR4) to downstream autophagy (MyD88–Beclin1) with therapeutic antibody testing

Limitations

  • Preclinical nature; human interventional data are lacking
  • Quantitative clinical associations and sample sizes for proteomics were not detailed in the abstract

Future Directions: Assess circulating HSP90α as a biomarker, evaluate safety/efficacy of HSP90α blockade, and explore combination strategies targeting NETosis in sepsis.

Platelets are crucial to the development of thrombosis and coagulation abnormalities in sepsis, but the mechanisms by which they contribute to these pathological processes are not fully understood. Here, we identify a key role for platelet-released heat shock protein 90α (HSP90α) in driving neutrophil extracellular trap (NET) formation and supporting thromboinflammation during sepsis. Proteomic analysis of platelets from patients with sepsis showed a significant increase in HSP90α, which we traced back to trafficking pathways originating from megakaryocytes. When activated, platelets translocate HSP90α to their plasma membrane and release it into the extracellular space in both free and exosome-associated forms. Extracellular HSP90α acts as a damage-associated molecular pattern that binds to toll-like receptor 4 (TLR4) on neutrophils. This binding activates a downstream MyD88-Beclin 1 signaling pathway, triggering autophagy and leading to NET formation. Blocking extracellular HSP90α with a neutralizing monoclonal antibody significantly reduced NET formation both in vitro and in vivo, resulting in decreased sepsis-related thrombosis and inflammation. This platelet-HSP90α-TLR4-autophagy-NET pathway not only deepens our understanding of platelet-induced immunothrombosis but also suggests potential targets for therapies aimed at reducing coagulation problems and organ failure in septic patients.